Financial information for the third quarter of 2014

• Cash, cash equivalent and financial instruments amounting to 74.7 million euros

• Cash horizon to end of 2017 unchanged

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class therapeutic antibodies for cancer and inflammatory diseases, today announced its revenues and cash position for the first nine months of 2014.
Cash, cash equivalents and financial instruments of the Company amounted to 74.7 million euros as at September 30, 2014 including the research tax credit relating to the year 2013 (4.1 million euros) which was received in the third quarter of 2014. As at September 30, 2014, the financial liabilities of the Company amounted to 4.3 million euros. Based on its current programs, the Company estimates that it has sufficient cash to fund operation into end of 2017.